Llwytho...
Pharmacokinetics of single ascending doses of the P-glycoprotein inhibitor tariquidar in healthy subjects
We assessed the pharmacokinetics (PK), tolerability and safety of tariquidar (TQD), a P-glycoprotein (Pgp) inhibitor, after i.v. administration of single ascending doses. Employed doses were up to 4-fold higher than in previous clinical trials in cancer patients and are capable to inhibit Pgp at the...
Wedi'i Gadw mewn:
| Prif Awduron: | , , , , , , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
2012
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3689924/ https://ncbi.nlm.nih.gov/pubmed/23146816 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000343243 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|